KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Current Assets data on record, last reported at $1.9 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 20.37% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 20.37%, while the annual FY2025 figure was $1.9 billion, 20.37% up from the prior year.
  • Current Assets reached $1.9 billion in Q4 2025 per AMRX's latest filing, up from $1.8 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.9 billion in Q4 2025 and bottomed at $1.3 billion in Q1 2023.
  • Average Current Assets over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2021.
  • Peak YoY movement for Current Assets: dropped 12.07% in 2021, then grew 20.37% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.5 billion in 2021, then fell by 7.12% to $1.4 billion in 2022, then dropped by 2.41% to $1.4 billion in 2023, then grew by 15.24% to $1.6 billion in 2024, then increased by 20.37% to $1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.9 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.5 billion in Q1 2025.